Camber Capital Management’s AbbVie ABBV Stock Holding History

Camber Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,000,000	Closed	-$107M	–	33
2020 Q4	$107M	Buy	+1,000,000	New	+$96.1M	3.76%	13

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Camber Capital Management's ABBV Position: Q2 2020 in Review

Camber Capital Management sold out of AbbVie (ABBV) in Q2 2020, closing a stake of 1,200,000 shares — an estimated $91.4M sold.

Camber Capital Management first reported a position in ABBV in Q1 2015 and held it in 4 quarters. The position peaked at $91.4M in Q1 2020. 2,412 funds tracked by Wall St. Rank hold ABBV as of Q2 2020.

Camber Capital Management reported no remaining AbbVie position as of Q2 2020 after selling out during the quarter.
Camber Capital Management sold 1,200,000 AbbVie shares in Q2 2020, an estimated $91.4M.
Camber Capital Management first reported a position in AbbVie in Q1 2015 and held it in 4 quarters.
Camber Capital Management's AbbVie position peaked at $91.4M in Q1 2020.
2,412 funds tracked by Wall St. Rank held AbbVie as of Q2 2020.

Based on Camber Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.